Tim-3 has gained prominence as a potential candidate for cancer immunotherapy, and in vivo blockade of Tim-3 with other checkpoint receptors enhances antitumor immunity and suppresses tumor growth in several preclinical tumor models (39). Here, HAVCR2 is linked to neoplasm.